Increased brain VDAC1 protein levels correlate with behavioural performance in a ketamine murine model of schizophrenia and are attenuated by the mGluR2 modulator JNJ-46356479
Schizophrenia Research · 2026-09 · 295 · 228-235
DOI: 10.1016/j.schres.2026.06.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Schizophrenia Research, 2026-09. Verfasst von David Olivares-Berjaga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Neurociències, Schizophrenia Research Group - Institut d'Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Catalonia, Sp…. Hauptthemen laut MEDLINE: Schizophrenia, Voltage-Dependent Anion Channel 1, Receptors, Metabotropic Glutamate, Hippocampus. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hospital Clínic Barcelona Research Foundation - August Pi i Sunyer Institute of Biomedical Research, Generalitat de Catalunya Departament d'Innovacio Universitats I Empresa, Carlos III Health Institute.
Abstract (Originalsprache)
BACKGROUND: Schizophrenia (SZ) is a neurodevelopmental disorder involving excitatory/inhibitory imbalance and apoptotic dysregulation. VDAC1, a voltage-dependent anion channel protein located in the mitochondrial outer membrane, plays a pivotal role in mitochondria-mediated apoptosis. However, its involvement in SZ remains underexplored. OBJECTIVES: This study aimed to investigate VDAC1 protein levels in the prefrontal cortex (PFC) and hippocampus (HPC) of a postnatal ketamine-exposed mouse model of SZ, and to assess the effects of treatment with the metabotropic GLU receptor 2 (mGluR2) positive allosteric modulator JNJ-46356479 (JNJ). We also examined associations between VDAC1 expression, behavioural performance, and other apoptosis-related markers. METHODS: Male and Female C57BL/6 J mice were exposed to ketamine or saline on postnatal days (PND) 7, 9, and 11, and treated in adulthood with JNJ or vehicle. VDAC1 protein levels in the PFC and HPC were quantified by western blot. Previously acquired behavioural data and levels of apoptotic markers (Bax, Bcl-2, caspase-3) from the same animals were analysed in relation to VDAC1 expression. RESULTS: VDAC1 levels were significantly increased in the PFC of ketamine-exposed mice and partially normalised by JNJ treatment. VDAC1 levels in the PFC and HPC were positively correlated. Higher VDAC1 levels were associated with an increased Bax/Bcl-2 ratio and poorer cognitive and social performance, particularly in the Y-Maze and the Five-Trial Social Memory Tests. CONCLUSIONS: Our findings support VDAC1 as a potential molecular marker of apoptotic imbalance in SZ. JNJ treatment may exert neuroprotective effects by modulating VDAC1 levels, suggesting that glutamatergic modulation could offer novel therapeutic avenues targeting mitochondrial dysfunction in SZ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut de Neurociències, Schizophrenia Research Group - Institut d'Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Catalonia, Spain; Basic and Clinical Practice Department, Faculty of Medicine and H…
- Institut de Neurociències, Schizophrenia Research Group - Institut d'Investigacions Biomèdiques August Pi i Sunyer, IDIBAPS, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSA…
Förderung
- Hospital Clínic Barcelona Research Foundation - August Pi i Sunyer Institute of Biomedical Research
- Generalitat de Catalunya Departament d'Innovacio Universitats I Empresa
- Carlos III Health Institute
- European Commission
- Janssen Research and Development
- Universitat de Barcelona
Zitieren
APA
Olivares-Berjaga, D., Rodríguez, N., Martínez-Pinteño, A., Rubio-Unguetti, L., Parellada, E., Gassó, P., & Morén, C. (2026). Increased brain VDAC1 protein levels correlate with behavioural performance in a ketamine murine model of schizophrenia and are attenuated by the mGluR2 modulator JNJ-46356479. Schizophrenia Research, 295, 228-235. https://doi.org/10.1016/j.schres.2026.06.010
Vancouver
Olivares-Berjaga D, Rodríguez N, Martínez-Pinteño A, Rubio-Unguetti L, Parellada E, Gassó P, et al. Increased brain VDAC1 protein levels correlate with behavioural performance in a ketamine murine model of schizophrenia and are attenuated by the mGluR2 modulator JNJ-46356479. Schizophrenia Research. 2026;295:228-235. doi:10.1016/j.schres.2026.06.010
BibTeX
@article{OlivaresBerjaga2026,
author = {Olivares-Berjaga, David and Rodríguez, Natàlia and Martínez-Pinteño, Albert and Rubio-Unguetti, Laura and Parellada, Eduard and Gassó, Patricia and Morén, Constanza},
title = {Increased brain VDAC1 protein levels correlate with behavioural performance in a ketamine murine model of schizophrenia and are attenuated by the mGluR2 modulator JNJ-46356479},
journal = {Schizophrenia Research},
year = {2026},
volume = {295},
pages = {228--235},
doi = {10.1016/j.schres.2026.06.010}
}
EUVIMED